Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The social value of a QALY: raising the bar or barring the raise?

Donaldson C, Baker R, Mason H, Jones-Lee M, Lancsar E, Wildman J, Bateman I, Loomes G, Robinson A, Sugden R, Prades JL, Ryan M, Shackley P, Smith R.

BMC Health Serv Res. 2011 Jan 11;11:8. doi: 10.1186/1472-6963-11-8.

2.

Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project.

Baker R, Bateman I, Donaldson C, Jones-Lee M, Lancsar E, Loomes G, Mason H, Odejar M, Pinto Prades JL, Robinson A, Ryan M, Shackley P, Smith R, Sugden R, Wildman J; SVQ Research Team.

Health Technol Assess. 2010 May;14(27):1-162. doi: 10.3310/hta14270.

3.

Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life.

Rowen D, Brazier J, Mukuria C, Keetharuth A, Risa Hole A, Tsuchiya A, Whyte S, Shackley P.

Med Decis Making. 2016 Feb;36(2):210-22. doi: 10.1177/0272989X15619389. Epub 2015 Dec 15.

PMID:
26670663
4.
5.

Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.

Lieu TA, Ray GT, Ortega-Sanchez IR, Kleinman K, Rusinak D, Prosser LA.

Pharmacoeconomics. 2009;27(12):1005-16. doi: 10.2165/11314000-000000000-00000.

PMID:
19908925
6.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

7.

Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.

Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M.

Health Technol Assess. 2015 Feb;19(14):1-503, v-vi. doi: 10.3310/hta19140.

8.

Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.

Dickson R, Bagust A, Boland A, Blundell M, Davis H, Dundar Y, Hockenhull J, Martin Saborido C, Oyee J, Ramani VS.

Pharmacoeconomics. 2011 Dec;29(12):1051-62. doi: 10.2165/11591600-000000000-00000.

PMID:
21967156
9.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

10.

Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy.

Campbell F, Thokala P, Uttley LC, Sutton A, Sutton AJ, Al-Mohammad A, Thomas SM.

Health Technol Assess. 2014 Sep;18(59):1-120. doi: 10.3310/hta18590. Review.

11.

Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.

Saborido CM, Hockenhull J, Bagust A, Boland A, Dickson R, Todd D.

Health Technol Assess. 2010 Jun;14(31):iii-iv, 1-75. doi: 10.3310/hta14310. Review.

12.

The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.

Connock M, Burls A, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, Wailoo A, Abrams K, Cooper N, Sutton A, O'Hagan A, Moore D.

Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. Review.

14.
15.

Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.

Sharma P, Boyers D, Boachie C, Stewart F, Miedzybrodzka Z, Simpson W, Kilonzo M, McNamee P, Mowatt G.

Health Technol Assess. 2012;16(17):1-266. doi: 10.3310/hta16170. Review.

16.

Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.

Sutcliffe P, Connock M, Pulikottil-Jacob R, Kandala NB, Suri G, Gurung T, Grove A, Shyangdan D, Briscoe S, Maheswaran H, Clarke A.

Health Technol Assess. 2013 Nov;17(53):1-499, v-vi. doi: 10.3310/hta17530. Review.

17.

BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.

Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N, Barnes M, Ford G, Graham L; BoTULS investigators.

Health Technol Assess. 2010 May;14(26):1-113, iii-iv. doi: 10.3310/hta14260.

18.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

19.

A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.

Hockenhull J, Elremeli M, Cherry MG, Mahon J, Lai M, Darroch J, Oyee J, Boland A, Dickson R, Dundar Y, Boyle R.

Health Technol Assess. 2012;16(12):III-IV, 1-110. doi: 10.3310/hta16120. Review.

20.

Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation.

Murray A, Lourenco T, de Verteuil R, Hernandez R, Fraser C, McKinley A, Krukowski Z, Vale L, Grant A.

Health Technol Assess. 2006 Nov;10(45):1-141, iii-iv. Review.

Supplemental Content

Support Center